VCEL

+ Watchlist + Portfolio

Vericel Corp.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $39.44
52-Week Range: $28.95 – $49.32
Market Cap: $2.06B
P/E (TTM): 83.65
EPS (TTM): 0.48
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 5.55
PEG Ratio: —
Return on Equity: 7.16%
Return on Assets: 2.43%
Gross Margin: 74.56%
Operating Margin: 0.56%
Profit Margin: 7.91%
Current Ratio: 5.04
Debt/Equity: 0.25
Total Debt: $93.13M
Free Cash Flow: $55.54M
Revenue Growth: 22.50%
Earnings Growth: —
Enterprise Value: $1.99B

VCEL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$164.37M	$197.52M	$237.22M	$276.26M
Cost of Revenue	$54.58M	$61.94M	$65.12M	$70.66M
Gross Profit	$109.79M	$135.58M	$172.11M	$205.60M
Research & Development	$19.94M	$21.04M	$24.80M	$27.56M
Selling, General & Admin	$106.90M	$121.00M	$142.79M	$166.99M
Operating Expenses	$126.85M	$142.04M	$167.59M	$194.56M
Operating Income	-$17.06M	-$6.46M	$4.52M	$11.04M
EBITDA	-$11.64M	$2.86M	$16.63M	$29.55M
Pretax Income	-$15.99M	-$2.37M	$10.51M	$17.38M
Income Tax	$721.00K	$814.00K	$148.00K	$859.00K
Net Income	-$16.71M	-$3.18M	$10.36M	$16.52M
Diluted EPS	-0.35	-0.07	0.20	0.32
Diluted Shares	47.13M	47.59M	51.68M	52.15M

VCEL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$51.07M	$69.09M	$74.52M	$100.09M
Receivables	$46.54M	$58.36M	$61.38M	$84.63M
Inventory	$15.99M	$13.09M	$17.37M	$17.56M
Current Assets	$186.87M	$205.63M	$212.78M	$247.44M
Total Assets	$273.00M	$353.66M	$432.72M	$487.97M
Current Liabilities	$37.46M	$45.75M	$50.29M	$49.15M
Total Debt	$47.57M	$88.04M	$98.97M	$96.37M
Total Liabilities	$80.73M	$127.70M	$140.75M	$133.33M
Retained Earnings	-$400.00M	-$403.18M	-$392.81M	-$376.30M
Shareholders' Equity	$192.27M	$225.95M	$291.97M	$354.64M
Working Capital	$149.40M	$159.88M	$162.49M	$198.29M

VCEL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$17.69M	$35.31M	$58.16M	$51.91M
Capital Expenditure	-$7.60M	-$27.51M	-$63.97M	-$27.16M
Free Cash Flow	$10.09M	$7.80M	-$5.81M	$24.75M
Depreciation & Amortisation	$3.98M	$4.63M	$5.50M	$11.54M
Stock-Based Compensation	$37.18M	$32.33M	$36.49M	$38.77M
Investing Cash Flow	-$36.21M	-$3.13M	-$79.03M	-$43.94M
Financing Cash Flow	$1.04M	$3.62M	$19.05M	$7.07M
Net Change in Cash	-$17.47M	$35.80M	-$1.82M	$15.04M

VCEL Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$63.24M	$67.50M	$92.92M	$68.42M	$77.46M
Cost of Revenue	$16.63M	$17.92M	$19.79M	$19.16M	$21.05M
Gross Profit	$46.61M	$49.59M	$73.13M	$49.27M	$56.40M
Research & Development	$6.73M	$6.32M	$7.25M	$8.10M	$7.49M
Selling, General & Admin	$41.91M	$39.82M	$43.46M	$49.23M	$48.48M
Operating Expenses	$48.64M	$46.13M	$50.71M	$57.33M	$55.97M
Operating Income	-$2.03M	$3.45M	$22.41M	-$8.06M	$434.00K
EBITDA	$2.43M	$8.18M	$27.35M	-$2.88M	$5.99M
Pretax Income	-$553.00K	$5.07M	$24.10M	-$6.30M	$2.21M
Net Income	-$553.00K	$5.07M	$23.24M	-$6.30M	$2.21M
Diluted EPS	-0.01	0.10	0.45	-0.12	0.04
Diluted Shares	50.37M	51.91M	52.07M	50.77M	52.31M

VCEL Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$80.53M	$100.40M	$100.09M	$109.30M	$125.36M
Receivables	$64.29M	$60.43M	$84.63M	$72.38M	$75.71M
Inventory	$16.83M	$18.16M	$17.56M	$18.35M	$18.38M
Current Assets	$204.58M	$221.97M	$247.44M	$244.06M	$264.73M
Total Assets	$435.61M	$453.27M	$487.97M	$485.63M	$502.87M
Current Liabilities	$41.13M	$45.58M	$49.15M	$47.16M	$52.53M
Total Debt	$99.76M	$98.01M	$96.37M	$94.54M	$92.65M
Total Liabilities	$128.80M	$131.42M	$133.33M	$129.40M	$132.82M
Retained Earnings	-$404.61M	-$399.54M	-$376.30M	-$382.60M	-$380.39M
Shareholders' Equity	$306.81M	$321.86M	$354.64M	$356.23M	$370.04M
Working Capital	$163.44M	$176.38M	$198.29M	$196.91M	$212.20M

VCEL Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$8.21M	$22.08M	$15.01M	$16.38M	$16.19M
Capital Expenditure	-$8.13M	-$2.63M	-$2.19M	-$1.26M	-$1.93M
Free Cash Flow	$81.00K	$19.45M	$12.83M	$15.13M	$14.26M
Depreciation & Amortisation	$2.83M	$2.94M	$3.09M	$3.27M	$3.62M
Stock-Based Compensation	$10.14M	$8.70M	$8.42M	$11.29M	$9.08M
Investing Cash Flow	-$9.03M	-$3.38M	-$16.39M	-$4.20M	-$2.82M
Financing Cash Flow	$1.64M	$1.17M	$1.06M	-$2.98M	$2.69M
Net Change in Cash	$827.00K	$19.87M	-$311.00K	$9.20M	$16.06M

Market Snapshot

About

Vericel Corp. is a leader in advanced therapies for the sports medicine and severe burn care markets. The company commercializes autologous cell therapy products including MACI for cartilage repair and Epicel for severe burns.